SEC Filing Summary: Genesis Biopharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Genesis Biopharma, Inc. (not IOVANCE Biotherapeutics, Inc.) on June 16, 2011, reporting events occurring on June 13, 2011. The company is incorporated in Nevada and headquartered in Los Angeles, California.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance data.
Material Changes
- Board Appointment: Effective June 13, 2011, the Company appointed Martin Schroeder to its Board of Directors.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The sole purpose of the report is to disclose the new director appointment.
Key Facts for Investor Verification
- Verify the background and qualifications of the newly appointed director, Martin Schroeder.
- Confirm the current corporate name is Genesis Biopharma, Inc., as the input metadata referenced IOVANCE Biotherapeutics, Inc., which is not mentioned in the filing text.
- Review the attached press release (Exhibit 99.1) for additional details regarding the appointment.